16 September 2026 editorial review · Item
ASITI-201 (proinsulin peptide / calcitriol liposomes): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: reviewed; no confirmed content change. Current item
lastReviewed: 2026-08-27T00:00:00.000Z. - Claim check: The 2 July ANZCTR update reports Part A complete and Part B recruiting, with 36 planned and 27 accrued. UQ's first-dose announcement is not an outcome table. Adult, HLA and residual C-peptide eligibility and short follow-up were checked.
- Primary publication/regulatory sources checked or consulted: TrialReview.aspx?id=387349.